| Roche moves Taspoglutide into phase III trials | Posted on 10/06/2008 in Pharmaceutical Company Product News Roche has announced that following positive phase II results for taspoglutide, the compound has been moved into phase III clinical trials.
The compound is the first once-weekly human glucagon-like peptide-1 (GLP-1) for the treatment of diabetes from Roche and Ipsen.
Results for the drug were reported at the congress of the American Diabetes Association, with the compound found to be efficacious and generally well-tolerated in type 2 diabetes patients, with significant glucose control improvements and weight loss seen after eight weeks.
The phase III clinical programme for taspoglutide is expected to start in the second half of this year.
Professor Michael Nauck, head of the Diabeteszentrum Bad Lauterberg, Germany, said: "These data show that taspoglutide is a promising and highly efficacious once weekly treatment for obese patients with type 2 diabetes mellitus no longer controlled on oral antidiabetic medications."
He added that drug-induced weight loss is especially beneficial for these patients and added that he awaited the publication of phase III results with interest.
Last month, Roche announced the results of a survey suggesting that 94 per cent of patients with type 2 diabetes had not attended any courses to support the management of their condition.Other news stories from 10/06/2008
Read more in the Zenopa News Archive
How this news is generated
|  |
|
